Skip to main content
PM Immunity Nebeling
© DZNE/Felix Nebeling

News categories: Publication

Study reveals dynamic interactions between brain tumors and immune cells

Glioblastoma, the most common and aggressive brain tumor in adults, is difficult to treat because this cancer can invade the surrounding brain tissue and spread far beyond the original tumor mass. Researchers from the DZNE, the University Hospital Bonn (UKB), and ImmunoSensation³ at the University of Bonn have observed this infiltration process in the living brain using high-tech microscopy. Their study is based on research in mice with a form of brain tumor that closely resembles human glioblastoma.

The findings, published in the journal *Immunity*, reveal complex and context-dependent interactions between glioblastoma cells and the brain’s immune cells, known as microglia. These cells patrol the tissue in search of threats. The findings suggest that they are not merely passive observers, but actively influence both the containment and spread of the tumor.

The researchers captured these processes using “three-photon microscopy,” which utilizes infrared light. They focused on the “distant infiltration zone.” This area of tissue is located several millimeters away from the primary tumor.

Changing Behavior

Among other things, the team found that the behavior of microglia changed as the tumor spread. When only a few tumor cells were present, the microglia were particularly mobile and highly active in their “surveillance function”—that is, in scanning the brain. However, as infiltration increased, this immune response waned. The researchers also investigated the consequences of deactivating a specific surface receptor through which microglia perceive their environment. Furthermore, they analyzed how a drastic reduction in immune cells affected tumor spread.

“Our data show that interactions between tumor cells and microglia play an important role in the spread of glioblastoma,” says Dr. Felix Nebeling, first author of the study. “Targeting the microglia - for example, with drugs - could therefore be a promising approach to limiting tumor spread and improving treatment outcomes.”

Funding

The study involved the DZNE, the UKB, the University of Bonn, the University Medical Center Mannheim, and University College London.

Publication

Microglia-glioblastoma crosstalk mediates glioblastoma invasion at the far infiltration zone, Felix Nebeling et al., Immunity (2026), DOI: https://doi.org/10.1016/j.immuni.2026.03.010

Contact

Felix Nebeling
Klinik für Neuroonkologie am UKB
DZNE
E-Mail: felix.nebeling@ukbonn.de

 

Related news

News Icon

News categories: Publication

Malaria Causes Permanent Damage to Phagocytes in the Spleen

Macrophages formed in the bone marrow can only assume the function of embryonal phagocytes, or “scavenger cells,” to a certain degree according to a study by the University of Bonn and the Peter Doherty Institute for Infection and Immunity at the University of Melbourne. The researchers have demonstrated that malaria infection causes permanent damage to resident CD163 macrophages in the spleen, which are responsible for cleaning the blood, recycling iron and communicating with other cells involved in the body’s immune response.
View entry
Tracking glioblastoma cell spread in human brain tissue

News categories: Publication

Core2Edge: How tumor cells conquer the brain

Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor cells remain in the brain and the tumor recurs. Bonn researchers have now developed Core2Edge, a model based entirely on human tissue that captures these hard-to-access infiltration zones at the tumor margin. The model enables investigation of the invasive front and direct assessment of new drug candidates in human tissue - without the need for animal testing. The study of the Brain Tumor Translational Research Group has now been published in Nature Protocols.
View entry
Mikrochip zur Wiederherstellung zentralen Sehvermögens bei fortgeschrittener Makuladegeneration.

News categories: Publication

Approval of a Novel Retinal Implant Technology

A novel retinal implant is offering people with geographic atrophy the opportunity to regain part of their central vision for the first time. Geographic atrophy is a severe late stage of age-related macular degeneration. An international research team led by Prof. Frank G. Holz of the UKB and the University of Bonn demonstrated in an international clinical trial that the majority of participants experienced significant improvements in visual acuity. The novel retinal implant technology has now received approval for routine clinical use in Europe, making it available beyond clinical trials.
View entry

Back to the news overview